Italiano: Sem Ibrahimovic, Milan estreia com vitória sobre a Sampdoria com gol de Brahim Diaz

Atual vice-campeão, o Milan estreou na nova temporada da Serie A do Campeonato Italiano com vitória por 1 a 0 sobre a Sampdoria no estádio Luigi Ferraris nesta segunda-feira.

O gol da vitória rossoneri foi marcado por Brahim Diaz, aos 9 minutos do primeiro tempo.

Melhores momentos

play

3:12

Italiano: Milan marca no 1º tempo e bate a Sampdoria na estreia; veja os melhores momentos

Brahim Díaz fez o único gol da vitória por 1 a 0 fora de casa

Star+ chega dia 31 de agosto

---

O que você vai ver primeiro? Filmes, séries, produções originais, Os Simpsons ou os esportes ao vivo da ESPN? Para mais detalhes, clique aqui

A Sampdoria criou boas chances e deu trabalho ao Milan, especialmente no primeiro tempo, onde chegou a acertar o travessão dos rivais.

Porém, o Milan foi mais efetivo e soube se segurar na defesa na parte final da partida.

O Milan ainda não conta com Zlatan Ibrahimovic. O sueco de quase 40 anos ainda se recupera de uma lesão no joelho e deve voltar apenas no mês que vem.

Situação do campeonato

Com o resultado, o Milan abre sua campanha na Serie A com três pontos e já sobe para o pelotão de cima da tabela.

Já a Sampdoria fica sem pontos após a primeira rodada.

play

0:19

Sampdoria x Milan: Gabbiadini coloca curva na bola, Maignan espalma com uma das mãos e ainda é salvo pelo travessão

Sampdoria e Milan se enfrentaram pelo Campeonato Italiano

O cara: Brahim Diaz

O meia espanhol foi o destaque do time do Milan na partida e converteu na melhor chance criada, o suficiente para dar a vitória aos visitantes na rodada de abertura.

Com o empréstimo do Real Madrid renovado por mais duas temporadas e a camisa 10 nas cosas, Diaz promete ser um dos principais nomes do Milan na temporada.

Próximos jogos

O Milan volta a jogar no domingo, novamente pela Série A italiana, no San Siro, contra o Cagliari, às 15h45 (Brasília).

Já a Sampdoria viaja para enfrentar o Sassuolo no mesmo dia pelo Italiano.

Ficha técnica

Sampdoria 0 x 1 Milan

Gols: Brahim Diaz

SAMPDORIA: Audero; Bereszynski, Yoshida, Colley e Augello (Murru); Thorsby, Ekdal (Adrien), Damsgaard e Candreva; Gabbiadini (Verre) e Quagliarella. Técnico: Roberto D'Aversa

MILAN: Maignan; Calabria (Romagnoli), Kjaer, Tomori e Hernandez; Krunic, Tonali, Saelemaekers (Florenzi), Brahim Diaz (Bennacer) e Rafael Leão (Rebic); Giroud. Técnico: Stefano Pioli

https://www.espn.com.br/futebol/artigo/_/id/9100440/italiano-sem-ibrahimovic-milan-estreia-com-vitoria-sobre-a-sampdoria-com-gol-de-brahim-diaz

FDA-Pfizer-BioNTech's COVID Vaccine Gets Full Approval From The FDA

 

Pfizer-BioNTech's COVID Vaccine Gets Full Approval From The FDA

Updated August 23, 20212:58 PM ET 

SCOTT HENSLEY

Twitter

3-Minute Listen

• Download

A nurse is handed a dose of the Pfizer COVID-19 vaccine before administering it to a college student during a mobile vaccination clinic at California State University, Long Beach on Aug. 11.

Patrick T. Fallon/AFP via Getty Images

The Food and Drug Administration has formally approved Pfizer's COVID-19 vaccine. The widely anticipated decision replaces the emergency use authorization granted by the agency last December.

The vaccine, developed by Pfizer and its partner BioNTech, is the first COVID-19 vaccine to be subject to a full review by the U.S. regulator and to get an approval that puts the vaccine on par with other marketed vaccines.

The full approval could make it easier for employers, the military and universities to mandate vaccination and may reassure some people who are hesitant about the vaccine.

"While this and other vaccines have met the FDA's rigorous, scientific standards for emergency use authorization, as the first FDA-approved COVID-19 vaccine, the public can be very confident that this vaccine meets the high standards for safety, effectiveness, and manufacturing quality the FDA requires of an approved product," acting FDA Commissioner Janet Woodcock said in a statement.

President Biden seized on the announcement in remarks to the nation on Monday afternoon to press for more people to get vaccinated as soon as possible.

"Let me say this loudly and clearly: If you're one of the millions of Americans who said that they will not get the shot until it has full and final approval of the FDA, it has now happened," he said. "The moment you've been waiting for is here. It's time for you to go get your vaccination. Get it today."

The president also encouraged businesses to "step up their vaccine requirements."

SHOTS - HEALTH NEWS

New Evidence Points To Antibodies As A Reliable Indicator Of Vaccine Protection

Approval could lead to more vaccinations

A June poll from the Kaiser Family Foundation found that 31% of unvaccinated people said they would be more likely to get a COVID-19 vaccine once one receives full approval from the FDA.

"While millions of people have already safely received COVID-19 vaccines, we recognize that for some, the FDA approval of a vaccine may now instill additional confidence to get vaccinated," Woodcock said. "Today's milestone puts us one step closer to altering the course of this pandemic in the U.S."

The FDA's full approval applies to people 16 and older. Those ages 12 through 15 can still receive the vaccine under the existing emergency use authorization.

There is no timeline for children under 12

That authorization does not extend to children under the age of 12. FDA officials have acknowledged the interest in vaccination for children in that age group but were unable Monday to provide a timeline for a decision on use of the vaccine for those under 12.

"Currently there are still trials ongoing here," Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, told reporters. "The agency has to wait for the companies to submit. ... Obviously, we will move swiftly, but first the trials have to be finished ... and the data need to be submitted to us."

The FDA acted Monday without convening a customary public meeting of expert advisers to vet information about the vaccine and make recommendations to the regulator.

As part of the approval process, the vaccine also got a brand name: Comirnaty. The FDA says that's pronounced "koe-mir'-na-tee."

As of Sunday, 73% of adults in the U.S. have had at least one dose of the Pfizer, Moderna or Johnson & Johnson vaccines. Pfizer's vaccine is most commonly administered, accounting for about 56% of the doses administered overall, according to data from the Centers for Disease Control and Prevention.

Moderna's COVID-19 vaccine remains under the FDA's review, but its approval is expected to follow in the near future.